Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioCardia, Inc.BCDA · Entity 7752 | Director · President and CEO | September 29, 2026 | October 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioCardia, Inc.
Report date September 29, 2026 · Filed October 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 384,885 |
Reported balance
After 2026-09-29 transaction · row 1
1 source rowRow 1 · 2026-09-29 · Purchase · Acquired 1,000 · Balance 384,885 F1: This transaction was executed in multiple trades ranging from $1.02 to $1.05 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades ranging from $1.02 to $1.05 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 11, 2022 Filed May 13, 2022 22:32 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseCommon Stock | 1,000 | $1.30 | $1,300.00 |
DisclosureSEC source: 0001437749-22-012420 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,143 F1 · price: This transaction was executed in multiple trades ranging from $1.29 to $1.30 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| April 29, 2022 Filed May 2, 2022 12:00 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseCommon Stock | 2,700 | $1.61 | $4,347.00 |
DisclosureSEC source: 0001437749-22-010339 · rdgdoc.xml · nonDerivative · entry 2 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,143 F2 · price: This transaction was executed in multiple trades ranging from $1.60 to $1.63 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| April 28, 2022 Filed May 2, 2022 12:00 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseCommon Stock | 2,300 | $1.59 | $3,657.00 |
DisclosureSEC source: 0001437749-22-010339 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,443 F1 · price: This transaction was executed in multiple trades ranging from $1.56 to $1.66 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| April 18, 2022 Filed Apr 19, 2022 01:17 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseCommon Stock | 13,500 | $1.39 | $18,700.20 |
DisclosureSEC source: 0001437749-22-009166 · rdgdoc.xml · nonDerivative · entry 2 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,143 F2 · price: This transaction was executed in multiple trades ranging from $1.37 to $1.40 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| April 14, 2022 Filed Apr 19, 2022 01:17 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | GrantStock Option (right to buy) · Derivative | 141,000 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0001437749-22-009166 · rdgdoc.xml · derivative · entry 3 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,000 Underlying: Common Stock · 141,000 shares Expires 2032-04-14 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 1/48th of the shares on May 14, 2022, and each month thereafter, subject to the Reporting Person continuing as a service provider through such date. Read SEC document |
| April 14, 2022 Filed Apr 19, 2022 01:17 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | GrantCommon Stock | 76,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-009166 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,643 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. 100% of the RSUs vested on April 14, 2022. Read SEC document |
| January 11, 2022 Filed Apr 14, 2023 23:52 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseCommon Stock | 100 | $1.87 | $187.00 |
DisclosureSEC source: 0001437749-23-010354 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 353,715 Read SEC document |
| November 18, 2021 Filed Nov 18, 2021 22:28 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseCommon Stock | 5,000 | $2.20 | $11,000.00 |
DisclosureSEC source: 0001437749-21-027108 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,909 Read SEC document |
| August 17, 2021 Filed Aug 18, 2021 22:43 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseCommon Stock | 3,500 | $2.94 | $10,290.00 |
DisclosureSEC source: 0001437749-21-020444 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,909 F1 · shares: This transaction was executed in multiple trades from $2.93 to $2.96 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares sold at each separate price. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 22:16 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | Tax withholdingCommon Stock | 11,572 | $4.35 | $50,338.20 |
DisclosureSEC source: 0001437749-21-014634 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,409 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested on April 21, 2021 and does not represent a sale by the Reporting Person. Read SEC document |
| April 21, 2021 Filed Apr 28, 2021 00:24 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | GrantStock Option (right to buy) · Derivative | 177,470 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0001437749-21-009941 · rdgdoc.xml · derivative · entry 2 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,470 Underlying: Common Stock · 177,470 shares Expires 2031-04-21 F2 · derivative.exercise_date: The option vests and becomes exercisable as to 1/48th of the shares on May 21, 2021 and each month thereafter, subject to the Reporting Person continuing as a service provider through such date. Read SEC document |
| April 21, 2021 Filed Apr 28, 2021 00:24 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | GrantCommon Stock | 33,581 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-009941 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,981 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. 100% of the RSUs vested on April 21, 2021. Read SEC document |
| December 01, 2020 Filed Dec 2, 2020 02:34 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseCommon Stock | 1,000 | $2.49 | $2,487.70 |
DisclosureSEC source: 0001437749-20-024679 · rdgdoc.xml · nonDerivative · entry 3 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,400 F3 · price: This transaction was executed in multiple trades ranging from $2.48 to $2.49 per share. The price reported above reflects the weighted average per share purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 27, 2020 Filed Dec 2, 2020 02:34 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseCommon Stock | 3,200 | $2.37 | $7,580.16 |
DisclosureSEC source: 0001437749-20-024679 · rdgdoc.xml · nonDerivative · entry 2 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,400 F2 · price: This transaction was executed in multiple trades ranging from $2.36 to $2.38 per share. The price reported above reflects the weighted average per share purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 27, 2020 Filed Dec 2, 2020 02:34 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | SaleCommon Stock | 3,200 | $2.31 | $7,379.84 |
DisclosureSEC source: 0001437749-20-024679 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,200 F1 · price: This transaction was executed in multiple trades ranging from $2.28 to $2.32 per share. The price reported above reflects the weighted average per share sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares sold at each separate price. Read SEC document |
| November 13, 2020 Filed Nov 13, 2020 23:33 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseCommon Stock | 500 | $2.09 | $1,046.00 |
DisclosureSEC source: 0001437749-20-023869 · rdgdoc.xml · nonDerivative · entry 2 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,400 Read SEC document |
| November 12, 2020 Filed Nov 13, 2020 23:33 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseCommon Stock | 2,000 | $2.07 | $4,130.00 |
DisclosureSEC source: 0001437749-20-023869 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,900 F1 · price: This transaction was executed in multiple trades ranging from $2.06 to $2.07 per share. The price reported above reflects the weighted average per share sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares sold at each separate price. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 11:15 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseCommon Stock | 2,500 | $1.98 | $4,950.00 |
DisclosureSEC source: 0001437749-20-023429 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,900 Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 01:15 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | Tax withholdingCommon Stock | 15,159 | $2.40 | $36,381.60 |
DisclosureSEC source: 0001437749-20-014423 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,400 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested on June 30, 2020 and does not represent a sale by the Reporting Person. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 23:20 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | GrantStock Option (right to buy) · Derivative | 55,130 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001437749-20-008737 · rdgdoc.xml · derivative · entry 2 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,130 Underlying: Common Stock · 55,130 shares Expires 2030-04-24 F2 · derivative.exercise_date: The option vests and becomes exercisable as to 1/48th of the shares on May 24, 2020 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 23:20 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | GrantCommon Stock | 37,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-20-008737 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,559 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. 100% of the RSUs vest on June 30, 2020. Read SEC document |
| April 22, 2020 Filed Apr 28, 2020 01:00 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | GrantCommon Stock | 400 | $3.41 | $1,365.64 |
DisclosureSEC source: 0001437749-20-008622 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,479 F1 · balance_after: This transaction was executed in multiple trades at prices ranging from $3.39 to $3.45 per share. The price reported above reflects the weighted average per share purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 24, 2020 Filed Mar 26, 2020 21:30 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseCommon Stock | 1,200 | $2.90 | $3,480.00 |
DisclosureSEC source: 0001437749-20-006236 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,911 F1 · price: This transaction was executed in multiple trades at prices ranging from $2.75 to $3.59 per share. The price reported above reflects the weighted average per share purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 11:30 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseCommon Stock | 400 | $2.95 | $1,180.00 |
DisclosureSEC source: 0001437749-20-005810 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,711 F1 · price: This transaction was executed in multiple trades at prices ranging from $2.93 to $2.99 per share. The price reported above reflects the weighted average per share purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 18, 2020 Filed Mar 19, 2020 20:02 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseCommon Stock | 3,300 | $2.53 | $8,349.00 |
DisclosureSEC source: 0001437749-20-005680 · rdgdoc.xml · nonDerivative · entry 2 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,311 F2 · price: This transaction was executed in multiple trades at prices ranging from $2.33 to $2.69 per share. The price reported above reflects the weighted average per share purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 20:02 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseCommon Stock | 200 | $3.66 | $732.00 |
DisclosureSEC source: 0001437749-20-005680 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,011 F1 · price: This transaction was executed in multiple trades at prices ranging from $3.30 to $3.73 per share. The price reported above reflects the weighted average per share purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 10:09 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseCommon Stock | 3,400 | $3.15 | $10,710.00 |
DisclosureSEC source: 0001437749-20-005217 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,811 F1 · price: This transaction was executed in multiple trades at prices ranging from $3.075 to $3.80 per share. The price reported above reflects the weighted average per share purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 11, 2020 Filed Mar 28, 2020 01:56 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | Tax withholdingCommon Stock | 4,958 | $3.60 | $17,848.80 |
DisclosureSEC source: 0001437749-20-006391 · rdgdoc.xml · nonDerivative · entry 2 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,079 F3 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs and does not represent a sale by the Reporting Person. F2 · balance_after: This share amount reflects the number of shares beneficially owned as of the filing date of this Form 4. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 20:51 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseCommon Stock | 4,000 | $3.67 | $14,676.00 |
DisclosureSEC source: 0001437749-20-000142 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,411 F1 · price: This transaction was executed in multiple trades at prices ranging from $3.59 to $3.6899 per share. The price reported above reflects the weighted average per share purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| October 18, 2019 Filed Oct 21, 2019 20:54 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseCommon Stock | 200 | $4.34 | $868.00 |
DisclosureSEC source: 0001437749-19-020333 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,411 F1 · price: This transaction was executed in multiple trades at prices ranging from $4.344 to $4.345 per share. The price reported above reflects the weighted average per share purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| October 09, 2019 Filed Oct 11, 2019 11:21 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseCommon Stock | 200 | $3.99 | $798.00 |
DisclosureSEC source: 0001437749-19-019931 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,211 Read SEC document |
| October 04, 2019 Filed Oct 5, 2019 00:22 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseCommon Stock | 700 | $3.64 | $2,545.90 |
DisclosureSEC source: 0001437749-19-019734 · rdgdoc.xml · nonDerivative · entry 2 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,011 F2 · price: This transaction was executed in multiple trades at prices ranging from $3.44 to $4.07 per share. The price reported above reflects the weighted average per share purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| October 03, 2019 Filed Oct 5, 2019 00:22 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseCommon Stock | 5,000 | $3.45 | $17,225.00 |
DisclosureSEC source: 0001437749-19-019734 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,311 F1 · price: This transaction was executed in multiple trades at prices ranging from $3.41 to $3.49 per share. The price reported above reflects the weighted average per share purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 27, 2019 Filed Mar 28, 2020 01:56 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | GrantCommon Stock | 12,126 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-20-006391 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,037 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. 100% of the RSUs vest on January 29, 2020. F2 · balance_after: This share amount reflects the number of shares beneficially owned as of the filing date of this Form 4. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 20:41 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseWarrant (right to buy) · Derivative | 67,484 | Not disclosed Strike: $6.30 | Not disclosed |
DisclosureSEC source: 0001437749-19-016065 · rdgdoc.xml · derivative · entry 4 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,484 Underlying: Common Stock · 67,484 shares Expires 2024-08-06 F1 · shares: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. F1 · price: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. F1 · derivative.underlying_shares: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 20:41 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | ConversionConvertible promissory note · Derivative | Not disclosed | $0.00 Strike: $3.00 | $200,000.00 |
DisclosureSEC source: 0001437749-19-016065 · rdgdoc.xml · derivative · entry 3 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 67,484 shares Expires 2020-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. F1 · reported_value: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. F1 · derivative.underlying_shares: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 20:41 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | ConversionCommon Stock | 67,484 | $3.00 | $202,452.00 |
DisclosureSEC source: 0001437749-19-016065 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,311 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. Read SEC document |
| July 05, 2019 Filed Aug 8, 2019 20:41 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseConvertible promissory note · Derivative | Not disclosed | $200,000.00 Strike: $8.00 | $200,000.00 |
DisclosureSEC source: 0001437749-19-016065 · rdgdoc.xml · derivative · entry 2 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 25,000 shares Expires 2020-01-05 F1 · derivative.exercise_price: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. F1 · reported_value: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. F1 · derivative.underlying_shares: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 10:02 UTC | BioCardia, Inc. BCDA · Entity 7752 | PurchaseCommon Stock | 600 | $8.71 | $5,223.00 |
DisclosureSEC source: 0001437749-19-013101 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,827 F1 · price: This transaction was executed in multiple trades at prices ranging from $7.99 to $9.50 per share. The price reported above reflects the weighted average per share purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 26, 2019 Filed Jun 27, 2019 01:52 UTC | BioCardia, Inc. BCDA · Entity 7752 | PurchaseCommon Stock | 100 | $9.24 | $924.00 |
DisclosureSEC source: 0001437749-19-012849 · rdgdoc.xml · nonDerivative · entry 3 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,227 Read SEC document |
| June 25, 2019 Filed Jun 27, 2019 01:52 UTC | BioCardia, Inc. BCDA · Entity 7752 | PurchaseCommon Stock | 500 | $10.85 | $5,423.00 |
DisclosureSEC source: 0001437749-19-012849 · rdgdoc.xml · nonDerivative · entry 2 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,127 F1 · price: This transaction was executed in multiple trades at prices ranging from $10.00 to $11.95 per share. The price reported above reflects the weighted average per share purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 24, 2019 Filed Jun 27, 2019 01:52 UTC | BioCardia, Inc. BCDA · Entity 7752 | PurchaseCommon Stock | 100 | $10.95 | $1,094.50 |
DisclosureSEC source: 0001437749-19-012849 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,627 Read SEC document |
| June 20, 2019 Filed Jun 22, 2019 00:08 UTC | BioCardia, Inc. BCDA · Entity 7752 | PurchaseCommon Stock | 300 | $9.00 | $2,700.00 |
DisclosureSEC source: 0001437749-19-012461 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,527 Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 00:58 UTC | BioCardia, Inc. BCDA · Entity 7752 | PurchaseCommon Stock | 400 | $11.33 | $4,532.00 |
DisclosureSEC source: 0001437749-19-012312 · rdgdoc.xml · nonDerivative · entry 2 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,227 F2 · price: This transaction was executed in multiple trades at prices ranging from $11.00 to $12.16 per share. The price reported above reflects the weighted average per share purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 17, 2019 Filed Jun 20, 2019 00:58 UTC | BioCardia, Inc. BCDA · Entity 7752 | PurchaseCommon Stock | 400 | $9.84 | $3,936.00 |
DisclosureSEC source: 0001437749-19-012312 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,827 F1 · price: This transaction was executed in multiple trades at prices ranging from $9.225 to $10.05 per share. The price reported above reflects the weighted average per share purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 00:36 UTC | BioCardia, Inc. BCDA · Entity 7752 | PurchaseCommon Stock | 300 | $10.52 | $3,156.90 |
DisclosureSEC source: 0001437749-19-012007 · rdgdoc.xml · nonDerivative · entry 2 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,428 F1 · price: This transaction was executed in multiple trades at prices ranging from $9.25 to $11.16 per share. The price reported above reflects the weighted average per share purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 11, 2019 Filed Jun 14, 2019 00:36 UTC | BioCardia, Inc. BCDA · Entity 7752 | PurchaseCommon Stock | 100 | $8.23 | $822.50 |
DisclosureSEC source: 0001437749-19-012007 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,128 Read SEC document |
| June 07, 2019 Filed Jun 8, 2019 01:30 UTC | BioCardia, Inc. BCDA · Entity 7752 | PurchaseCommon Stock | 100 | $11.16 | $1,116.00 |
DisclosureSEC source: 0001437749-19-011642 · rdgdoc.xml · nonDerivative · entry 2 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,028 Read SEC document |
| June 06, 2019 Filed Jun 8, 2019 01:30 UTC | BioCardia, Inc. BCDA · Entity 7752 | PurchaseCommon Stock | 135 | $11.13 | $1,502.55 |
DisclosureSEC source: 0001437749-19-011642 · rdgdoc.xml · nonDerivative · entry 1 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,928 F1 · price: This transaction was executed in multiple trades at prices ranging from $11.00 to $12.00 per share. The price reported above reflects the weighted average per share purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 00:23 UTC | BioCardia, Inc. BCDA · Entity 7752 | PurchaseCommon Stock | 100 | $1.20 | $120.00 |
DisclosureSEC source: 0001437749-19-011512 · rdgdoc.xml · nonDerivative · entry 2 Altman Peter · CIK 0001647542 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 745,142 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.